EP2571498A1 - Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant - Google Patents

Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant

Info

Publication number
EP2571498A1
EP2571498A1 EP11720107A EP11720107A EP2571498A1 EP 2571498 A1 EP2571498 A1 EP 2571498A1 EP 11720107 A EP11720107 A EP 11720107A EP 11720107 A EP11720107 A EP 11720107A EP 2571498 A1 EP2571498 A1 EP 2571498A1
Authority
EP
European Patent Office
Prior art keywords
paracetamol
solution according
lipoic acid
acid
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11720107A
Other languages
German (de)
English (en)
Inventor
Vincenzo De Tommaso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raw Materials International - Swiss Branch LLC
Original Assignee
Raw Materials International - Swiss Branch LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raw Materials International - Swiss Branch LLC filed Critical Raw Materials International - Swiss Branch LLC
Priority to EP11720107A priority Critical patent/EP2571498A1/fr
Publication of EP2571498A1 publication Critical patent/EP2571498A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Definitions

  • compositions comprising lipoic acid as an antioxidant
  • the present invention is directed to a stable injectable pharmaceutical aqueous solution comprising a pharmaceutical compound and lipoic acid as an antioxidant.
  • Many pharmaceutical compounds are commercially available as stable injectable aqueous solutions. These pharmaceutical solutions usually comprise an antioxidant to guarantee long term stability of the solution.
  • EP 0 858 329 discloses a paracetamol aqueous solution comprising water, a polyol or a water soluble alkanol and a free radical scavenger or an anti- radical agent.
  • the solution to be stable, needs to be deoxygenated by bubbling an inert gas.
  • Preferred free radical scavengers are derivatives of ascorbic acid, organic compounds which bear at least one thiol function and polyols.
  • Lipoic acid is a well known natural compound. In 1966 its use for the treatment of diabetes was approved in Germany and in the 1980s it became available as a nutritional supplement for its known properties as an in vivo antioxidant. However, we are not aware of any use of lipoic acid as an antioxidant for aqueous pharmaceutical compositions.
  • lipoic acid as an antioxidant, produces injectable pharmaceutical solutions that are stable.
  • Pharmaceutical compounds that can be stabilized by the use of lipoic acid are not particularly limited and can for example belong to the category of analgesic, antipyretic, anti-inflammatory, anti-staminic, anti-emetic, antibiotic, corticosteroid, anti-depressive, anti-epilepsy and inotropic compounds.
  • a non-limiting list of pharmaceutical compounds useful in the present invention are: paracetamol, fructose 1,6 diphosphate, promethazine, amikacin, dobutamine and diclofenac.
  • the solution according to the present invention preferably comprises a non-ionic surfactant, whose presence is useful in dissolving lipoic acid.
  • the non- ionic surfactant used in the composition can be any non-ionic surfactant suitable for pharmaceutical compositions. Examples of preferred non-ionic surfactants are glychocolic acid, glycofurol, polyethylenglycol 200, polyethylene-glycol 300 and polyethylenglycol 400; the most preferred non-ionic surfactant is glychocolic acid.
  • the non-ionic surfactant is present in a weight ratio with lipoic acid comprised between 1 : 10 and 10 : 1, preferably from 5 : 1 to 1 : 5.
  • the invention is directed to the paracetamol solutions comprising lipoic acid as an antioxidant. More particularly, the invention is directed to a pharmaceutical composition comprising water, paracetamol, an amino sugar, a non-ionic surfactant and lipoic acid as an antioxidant. It is known that paracetamol, when stored in aqueous solutions tends to degrade with formation of p-aminophenol. It has been surprisingly found that lipoic acid can stabilize paracetamol in aqueous solution in a more effective way than thiol compounds. In fact, the aqueous solutions according to the invention do not require bubbling with an inert gas and are stable even in the presence of dissolved oxygen.
  • the concentration of lipoic acid to be used in paracetamol solutions according to the invention is preferably comprised between 0.05 g/L and 2 g/L, more preferably 0.1 and 1 g/L.
  • the paracetamol solutions according to the invention are solutions ready for use, i.e. solution wherein paracetamol is present in a concentration comprised between 5 and 20 g/L.
  • the solution can also comprise another active ingredient which is commonly used in combination with paracetamol.
  • the solution can also comprise a compound selected from the group consisting of an analgesic, an anti-inflammatory compound, an antiemetic, a corticosteroid, an antidepressive and an anti-epilepsy compound.
  • the aminosugar used in this embodiment of the present invention is important to help solubilization of paracetamol.
  • aminosugars useful in the present invention are: glucamine, glucosamine, chondrosamine and their N-alkyl derivatives such as N-methylglucamine.
  • the weight ratio between aminosugar and paracetamol preferably varies between 0.01 : 1 and 0.5 : 1. If the amount of aminosugar is too low, the solubility of paracetamol will be lower than desired.
  • aqueous solutions comprising paracetamol and lipoic acid are stable and do not require bubbling with an inert gas to remain stable for a long period.
  • the paracetamol solution is not degassed to remove oxygen.
  • the paracetamol aqueous solutions according to the invention are prepared by a process comprising : dissolving lipoic acid and aminosugar in water; when lipoic acid is solubilized, a non-ionic surfactant is added, preferably under stirring and the pH is brought to a value in the range from 9 to 10, preferably about 9.5, by adding a base, preferably NaOH; when also the surfactant is dissolved, paracetamol is added and the dispersion kept under stirring until complete solubilization is obtained; then, pH is brought to a value close to neutral, preferably from 5 to 8, more preferably from 5.5 to 6.5, most preferably about 6, by adding an acid, preferably phosphoric acid; the solution is brought to the final volume by addition of water and the pH of the final solution controlled and corrected to the previous value by adding the acid or the base previously used.
  • the obtained solution is then treated according to standard methods used in the pharmaceutical field to prepare sterile vials.
  • the solution can be filtered on a 0.22 ⁇ filter and bottled sterilely.
  • lipoic acid is used to stabilize aqueous solutions of fructose 1,6 sodium diphosphate.
  • Fructose 1,6 sodium diphosphate is highly soluble in water, thus it does not require addition of any cosolvent.
  • These solutions are based on water, fructose 1,6 diphosphate and lipoic acid.
  • the amount of lipoic acid required to achieve stabilization of the solution is comprised between 0.1 g/L and 5 g/l, preferably between 0.2 g/L and 2 g/L.
  • the amount of fructose 1,6 diphosphate in the solution, due to its solubility, can vary in a broad range.
  • a preferred concentration range is from 10 g/L to 200 g/L, more preferably between 50 and 150 g/L.
  • the solution is preferably prepared by adding the amount of lipoic acid and glychocolic acid in about 70 % of the final volume of water.
  • Lipoic acid is solubilized by adding a base, preferably sodium hydroxide. Then fructose 1,6 sodium diphosphate is added under stirring. The pH is maintained in the range from 4.5 and 5.5, preferably from 4.8 to 5.2. The solution is brought to the final volume with water.
  • the obtained solution is then treated according to standard methods used in the pharmaceutical field to prepare sterile vials.
  • the solution can be filtered on a 0.22 ⁇ filter and bottled sterilely.
  • Another preferred embodiment of the invention concerns the preparation of aqueous solutions of dobutamine chlorohydrate stabilized by lipoic acid.
  • Dobutamine chlorohydrate is commonly sold in 20 ml vials containing 250 mg of dobutamine. To stabilize this solution it is enough to add from 10 to 100 mg of lipoic acid .
  • the solution has a pH of from 3.5 to 4.5, preferably from 3.8 to 4.2.
  • the solution is preferably prepared by adding the amount of lipoic acid and glychocolic acid in about 70 % of the final volume of water.
  • Lipoic acid is solubilized by adding a base, preferably sodium hydroxide.
  • dobutamine chlorohydrate is added under stirring.
  • the pH is maintained in the range from 3.5 and 4.5, preferably from 3.8 to 4.2.
  • the solution is brought to the final volume with water.
  • Another preferred embodiment of the invention concerns the preparation of aqueous solutions of diclofenac stabilized by lipoic acid. Since diclofenac has low solubility in water, it is necessary to add one or more cosolvents. Suitable cosolvents are alcohols and glycols, such as propylene glycol, ethylene glycol, benzyl alcohol, and mixtures thereof. Normally, diclofenac is commercialized in 3 ml vials containing 75 mg of diclofenac, however, if desired, the solution can be prepared at different concentrations. When preparing 3 ml vials containing 75 mg of diclofenac, the total amount of cosolvent can vary from 300 mg to 1 g .
  • Preferred cosolvents are propylene glycol and benzyl alcohol .
  • Benzyl alcohol is added in an amount preferably comprised between 250 mg and 900 mg and propylene glycol in an amount preferably comprised between 50 mg and 250 mg .
  • the amount of lipoic acid is preferably comprised between 5 and 50 mg, more preferably from 5 to 25 mg .
  • the obtained solution is then treated according to standard methods used in the pharmaceutical field to prepare sterile 3 ml vials containing 75 mg of diclofenac.
  • the solution can be filtered on a 0.22 ⁇ filter and bottled sterilely.
  • a promethazine hydrochloride aqueous solution stabilized by lipoic acid is preferably prepared by adding lipoic acid and glychocolic acid to about 50 % of the final amount of water. NaOH is added to solubilized it.
  • The, promethazine is added under stirring and trisodium citrate is added to buffer the pH to a value preferably comprised between 5 and 6, more preferably between 5.2 and 5.6.
  • the solution is brought to the final volume with water.
  • the obtained solution is then treated according to standard methods used in the pharmaceutical field to prepare sterile 2 ml vials containing 50 mg of promethazine hydrochloride. For example, the solution can be filtered on a 0.22 ⁇ filter and bottled sterilely. Examples
  • Vials obtained by this procedure were stored at 25 °C for 1 year and at 40 °C for 6 months.
  • the samples were analyzed by HPLC according to European Pharmacopoeia 6.0 and the amount of impurities measured was within the limits indicated in the European Pharmacopoeia 6.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur une solution aqueuse pharmaceutique, injectable, stable, comprenant un composé pharmaceutique et de l'acide lipoïque en tant qu'anti-oxydant. Une liste non limitative de composés pharmaceutiques utiles dans la présente invention consiste en : le paracétamol, le fructose 1,6 diphosphate, la prométhazine, l'amikacine, la dobutamine et le diclofenac. Les solutions selon l'invention comprennent, de préférence, un agent tensio-actif non ionique qui aide à la solubilisation de l'acide lipoïque. Un agent tensio-actif non ionique préféré est l'acide glycocholique.
EP11720107A 2010-05-21 2011-05-18 Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant Withdrawn EP2571498A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11720107A EP2571498A1 (fr) 2010-05-21 2011-05-18 Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10163511A EP2389931A1 (fr) 2010-05-21 2010-05-21 Compositions pharmaceutiques aqueuses comprenant de l'acide lipoïque en tant qu'antioxydant
PCT/EP2011/058029 WO2011144650A1 (fr) 2010-05-21 2011-05-18 Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant
EP11720107A EP2571498A1 (fr) 2010-05-21 2011-05-18 Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant

Publications (1)

Publication Number Publication Date
EP2571498A1 true EP2571498A1 (fr) 2013-03-27

Family

ID=43049554

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10163511A Withdrawn EP2389931A1 (fr) 2010-05-21 2010-05-21 Compositions pharmaceutiques aqueuses comprenant de l'acide lipoïque en tant qu'antioxydant
EP11720107A Withdrawn EP2571498A1 (fr) 2010-05-21 2011-05-18 Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10163511A Withdrawn EP2389931A1 (fr) 2010-05-21 2010-05-21 Compositions pharmaceutiques aqueuses comprenant de l'acide lipoïque en tant qu'antioxydant

Country Status (4)

Country Link
EP (2) EP2389931A1 (fr)
AU (1) AU2011254651B2 (fr)
NZ (1) NZ603783A (fr)
WO (1) WO2011144650A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
US20160250392A1 (en) 2015-02-26 2016-09-01 Battelle Memorial Instute Implant with reactive oxygen species scavenging coating
JP7083091B2 (ja) * 2018-03-06 2022-06-10 ジェイオーコスメティックス株式会社 皮膚外用剤および水溶液
CN114886847B (zh) * 2022-06-21 2023-08-11 遂成药业股份有限公司 一种盐酸异丙嗪注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70974T1 (de) * 1987-12-04 1992-01-15 Asta Pharma Ag Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren.
DK0427247T3 (da) * 1989-11-09 1998-09-28 Asta Medica Ag Lægemiddel indeholdende R-alpha- lipoinsyre eller S-alphalipoinsyre som aktiv bestanddel
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
WO2000057876A1 (fr) * 1999-03-26 2000-10-05 Lipogenics, Inc. Preparations antioxydantes et procedes d'utilisation de telles preparations
DE19954321A1 (de) * 1999-11-11 2001-07-26 Asta Medica Ag Erleichterte Verabreichung von alpha-Liponsäure oder Derivaten derselben
ES2239582T3 (es) * 2000-01-20 2005-10-01 Innovet Italia S.R.L. Una composicion para tratar enfermedades articulares degenerativas.
US20030191064A1 (en) * 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
AU2005223618A1 (en) * 2004-03-17 2005-09-29 Arnold C. Takemoto Tissue detoxification and health supplements and methods of making and using them
US20100255109A1 (en) * 2007-08-06 2010-10-07 Biogenics, Inc. Stabilized antioxidant particles, composition comprising the same and method for preparing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2011144650A1 *

Also Published As

Publication number Publication date
NZ603783A (en) 2015-02-27
WO2011144650A1 (fr) 2011-11-24
EP2389931A1 (fr) 2011-11-30
AU2011254651B2 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
EP2307056B1 (fr) Compositions pharmaceutiques aqueuses stables contenant du paracetamol
EP1904052A1 (fr) Compositions pharmaceutiques liquides de docétaxel
JP6516831B2 (ja) シクロホスファミド液状濃縮物の製剤
EP2280688B1 (fr) Préparation pharmaceutique aqueuse
WO2013144814A1 (fr) Composition pharmaceutique prête-à-l'emploi stable de pemetrexed
EP2649993B1 (fr) Stabilisant d'acétaminophène
IL230308A (en) Medicinal product containing eporphine as an active ingredient
AU2011254651B2 (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
EP3206666A2 (fr) Compositions pharmaceutiques liquides contenant du pémétrexed
EP2875814B1 (fr) Composition liquide contenant un principe actif à base de taxane, son procédé de fabrication et préparation médicinale liquide
AU2011254651A1 (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
WO2009111294A1 (fr) Solutions de topotécan prêtes à l'emploi
EP3324936A1 (fr) Procédé pour produire une solution d'ester de bortézomib
CN115666579A (zh) 卡非佐米的稳定的即稀释型制剂
CN110090225B (zh) 一种依达拉奉氯化钠注射液及其制备方法
WO2013108180A1 (fr) Composition aqueuse de paracétamol pour injection
US8481781B2 (en) Formulations of canfosfamide and their preparation
WO2012120337A1 (fr) Compositions aqueuses de paracétamol et procédé de préparation
CA3137265A1 (fr) Composition pharmaceutique aqueuse stable et prete a l'emploi de pemetrexed
CN104244925B (zh) 盐酸氢吗啡酮溶液的提高的稳定性
KR100993291B1 (ko) 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법
EP3222271A1 (fr) Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160530

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161129

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170829